Compare ECVT & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ECVT | ANAB |
|---|---|---|
| Founded | 1935 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2017 | 2015 |
| Metric | ECVT | ANAB |
|---|---|---|
| Price | $11.35 | $55.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $12.60 | ★ $62.20 |
| AVG Volume (30 Days) | ★ 1.4M | 408.9K |
| Earning Date | 05-29-2026 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.79 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $723,515,000.00 | $91,280,000.00 |
| Revenue This Year | $6.38 | $135.51 |
| Revenue Next Year | $6.78 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 2.70 | ★ 432.03 |
| 52 Week Low | $5.24 | $14.01 |
| 52 Week High | $12.33 | $57.74 |
| Indicator | ECVT | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 54.74 | 59.87 |
| Support Level | $8.04 | $43.67 |
| Resistance Level | $11.85 | $57.65 |
| Average True Range (ATR) | 0.40 | 3.44 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 30.00 | 77.64 |
Ecovyst Inc is an integrated and provider of materials, specialty catalysts and services. Its products contribute to lower emissions and cleaner air, higher fuel efficiency and cleaner fuels, and key enablers to advance transition to clean energy. The company has two reporting segments: Ecoservices and Advanced Materials & Catalysts. Ecoservices provides sulfuric acid recycling to the North American refining industry for the production of alkylate and provides on-purpose virgin sulfuric acid for water treatment, mining, and industrial applications. Maximum revenue is generated from Ecoservices segment.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).